This page provides a comprehensive comparison between Alzheimer's Disease (AD) and Parkinson's Disease (PD), the two most common neurodegenerative disorders. While both conditions involve progressive neuronal loss, they differ significantly in their pathophysiology, clinical presentations, and therapeutic approaches.
flowchart TD
subgraph Alzheimer's_Disease
A1"Amyloid Precursor Protein" --> A2"Aβ Peptides"
A2 --> A3"Extracellular Plaques"
A4"Tau Protein" --> A5"Hyperphosphorylation"
A5 --> A6"Neurofibrillary Tangles"
end
subgraph Parkinson's_Disease
P1"Alpha-Synuclein" --> P2"Misfolding"
P2 --> P3"Oligomers"
P3 --> P4"Lewy Bodies"
end
subgraph Shared_Mechanisms
S1"Mitochondrial Dysfunction" --> S2"ATP Depletion"
S3"Oxidative Stress" --> S4"DNA/Lipid Damage"
S5"Neuroinflammation" --> S6"Microglial Activation"
S7"Protein Aggregation" --> S8"Cell Death"
end
A1 -.->|Common| S1
P1 -.->|Common| S1
A1 -.-> S3
P1 -.-> S3
A1 -.-> S5
P1 -.-> S5
A1 -.-> S7
P1 -.-> S7
| Feature |
Alzheimer's Disease |
Parkinson's Disease |
| Prevalence |
~6.5 million in US (age 65+) |
~1 million in US |
| Age of Onset |
Typically >65 years |
Typically >60 years |
| Primary Symptoms |
Memory loss, cognitive decline |
Motor symptoms (tremor, bradykinesia) |
| Core Pathology |
Amyloid-beta plaques, neurofibrillary tangles |
Lewy bodies (alpha-synuclein), dopaminergic neuron loss |
| Primary Brain Regions |
Hippocampus, cortex |
Substantia nigra, basal ganglia |
| Primary Neurotransmitter |
Acetylcholine |
Dopamine |
| Feature |
Alzheimer's Disease |
Parkinson's Disease |
| Main Aggregating Protein |
Amyloid-beta (Aβ), Tau |
Alpha-synuclein (α-syn) |
| Aggregate Type |
Extracellular plaques, intracellular tangles |
Intracellular Lewy bodies |
| Key Peptides |
Aβ40, Aβ42 |
α-syn monomers, oligomers |
| Toxic Species |
Aβ42 oligomers, soluble tau |
α-syn oligomers, preformed fibrils |
| Region |
Alzheimer's Disease |
Parkinson's Disease |
| Hippocampus |
Early, severe involvement |
Later involvement |
| Cortex |
Early, widespread |
Variable, later |
| Substantia Nigra |
Incidental |
Primary, severe |
| Basal Ganglia |
Secondary involvement |
Primary involvement |
| Brainstem |
Later stages |
Early involvement |
| Locus Coeruleus |
Early involvement |
Early involvement |
Shared Mechanisms:
- Mitochondrial dysfunction
- Oxidative stress
- Neuroinflammation (microglial activation)
- Protein misfolding and aggregation
- Autophagy-lysosomal pathway dysfunction
- Endoplasmic reticulum stress
- Synaptic dysfunction
Distinct Mechanisms:
- AD: Amyloid processing (APP metabolism), tau phosphorylation, Wnt signaling dysregulation
- PD: LRRK2 kinase dysfunction, mitochondrial complex I deficiency, PINK1/Parkin mitophagy defects
| Gene |
Risk/CA Allele |
Function |
| SNCA |
A53T, A30P (CA); Multiplications |
Alpha-synuclein encoding |
| LRRK2 |
G2019S (CA) |
Leucine-rich repeat kinase |
| PARKIN |
Recessive mutations |
E3 ubiquitin ligase |
| PINK1 |
Recessive mutations |
Mitochondrial kinase |
| GBA |
N370S, L444P |
Glucocerebrosidase |
| DJ-1 |
Recessive mutations |
Oxidative stress response |
| VPS35 |
D620N (CA) |
Retromer complex |
- Memory impairment (especially episodic memory) - earliest symptom
- Executive dysfunction - planning, reasoning, judgment
- Language problems - word-finding difficulty, anomia
- Visuospatial deficits - getting lost, spatial disorientation
- Behavioral changes - apathy, depression, agitation
- Psychiatric symptoms - hallucinations (later stages)
- Resting tremor - "pill-rolling" tremor
- Bradykinesia - slowness of movement
- Rigidity - lead-pipe or cogwheel
- Postural instability - falls
- Non-motor symptoms - depression, anxiety, sleep disorders, autonomic dysfunction
- Cognitive impairment - executive dysfunction, eventually dementia (PDD)
| Approach |
Alzheimer's Disease |
Parkinson's Disease |
| Cholinesterase Inhibitors |
Donepezil, Rivastigmine, Galantamine |
Rivastigmine (for PDD) |
| NMDA Antagonist |
Memantine |
Amantadine |
| Dopamine Precursor |
— |
Levodopa/Carbidopa |
| Dopamine Agonists |
— |
Pramipexole, Ropinirole |
| MAO-B Inhibitors |
— |
Selegiline, Rasagiline |
| COMT Inhibitors |
— |
Entacapone |
| Anticholinergics |
— |
Trihexyphenidyl |
| Target |
Alzheimer's Disease |
Parkinson's Disease |
| Amyloid |
Aducanumab, Lecanemab, Donanemab (anti-Aβ) |
— |
| Tau |
Anti-tau antibodies, kinase inhibitors |
— |
| Alpha-synuclein |
— |
Immunotherapies (PD01A, ABBV-951) |
| LRRK2 |
— |
DNL151, BIIB122 |
| GBA |
— |
Gene therapy approaches |
Both diseases share several mechanistic pathways that represent promising therapeutic targets:
- Neuroinflammation: TREM2 agonists (AD), CSF1R inhibitors
- Mitochondrial dysfunction: CoQ10, mitochondrial antioxidants
- Autophagy: mTOR inhibitors, autophagy enhancers
- Oxidative stress: N-acetylcysteine, glutathione boosters
- Synaptic protection: BDNF enhancers, synaptic stabilizers
While AD and PD are both neurodegenerative diseases with shared features including protein aggregation, neuroinflammation, and oxidative stress, they differ significantly in their primary protein pathology (amyloid-beta/tau vs. alpha-synuclein), primary brain regions affected, and clinical presentations. Understanding these similarities and differences is crucial for developing effective treatments and, potentially, disease-modifying therapies that may benefit both conditions.